Oral dnaJP1 - Adeona Pharmaceuticals

Drug Profile

Oral dnaJP1 - Adeona Pharmaceuticals

Alternative Names: AT-001; dnaJ peptide; dnaJP1

Latest Information Update: 04 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of California, San Diego
  • Developer Adeona Pharmaceuticals
  • Class Antirheumatics; Immunotherapies; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 31 Mar 2011 Discontinued - Phase-II for Rheumatoid arthritis in USA (PO)
  • 30 Nov 2010 Adeona Pharmaceuticals' dnaJP1 is available for licensing as of 30 Nov 2010. http://www.adeonapharma.com/dnajp1.php
  • 30 Sep 2009 Oral dnaJP1 is available for licensing worldwide (http://www.adeonapharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top